Eli Lil­ly: As do­nanemab fil­ing ap­proach­es, ex­ecs 'even more con­fi­den­t' in da­ta pack­age

Eli Lil­ly had a strong Q2, but un­sur­pris­ing­ly an­a­lysts don’t want to talk much about drugs al­ready ap­proved — their eyes are set firm­ly on Alzheimer’s hope­ful do­nanemab, a po­ten­tial block­buster in the mak­ing.

Lil­ly CEO David Ricks faced a wall of ques­tions Tues­day from an­a­lysts on the drug­mak­er’s Q2 earn­ings call look­ing to paint a pic­ture of Lil­ly’s hand as it pre­pares to file a BLA for do­nanemab lat­er this year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER